Response to "Denosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis".

Lv, Fang

Response to "Denosumab and Romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis". [electronic resource] - Bone 05 2020 - 115271 p. digital

Publication Type: Letter; Comment

1873-2763

10.1016/j.bone.2020.115271 doi


Antibodies, Monoclonal--adverse effects
Cardiovascular Diseases--epidemiology
Denosumab
Humans
Osteoporosis--drug therapy